Driehaus Capital Management 13F: Cuts SRRK Stake by $1.8M

Driehaus Capital Management has trimmed its stake in Scholar Rock Holding Corporation (NasdaqGS:SRRK), reducing its holdings by 32,644 shares. This represents a 1.7% decrease, leaving Driehaus with 1,920,233 shares valued at approximately $103.3 million as of the latest Form 13F filing with the SEC for the period ending May 15, 2026.

What Changed in Driehaus Capital Management's Scholar Rock Holding Corporation Position

Driehaus Capital Management reduced its holdings in Scholar Rock by 32,644 shares, decreasing its position by 1.7%. The firm now holds 1,920,233 shares valued at about $103.3 million. Previously, Driehaus held 1,952,877 shares.

Other Institutional Activity in Scholar Rock Holding Corporation

FMR LLC increased its holdings in Scholar Rock by 1,862,477 shares, ending with 17,243,152 shares worth about $847.7 million, marking a 12.1% increase. REDMILE GROUP, LLC significantly boosted its position by 3,845,775 shares to 9,066,621 shares, a 73.7% increase, valued at $445.7 million. BLACKROCK, INC. also increased its stake by 252,259 shares to a total of 7,469,293 shares, valued at approximately $367.2 million, marking a 3.5% rise. Meanwhile, SIREN, L.L.C. and SAMSARA BIOCAPITAL, LLC maintained their positions without change.

Scholar Rock Holding Corporation Stock Up 17.9%

Shares of NasdaqGS:SRRK traded near $53.79 on Friday. Scholar Rock has a market capitalization of approximately $6.45 billion and a forward P/E ratio of -22.7, indicating it is not currently profitable. The stock's 52-week range is between $27.07 and $53.86. It has a 50-day moving average of $47.68 and a 200-day moving average of $42.50. The company's beta is 0.695, suggesting lower volatility than the market. Scholar Rock also maintains a strong liquidity position with a current ratio of 8.639 and a quick ratio of 8.407.

Recent Earnings

Scholar Rock reported earnings with a negative EPS of -3.45, reflecting ongoing investments in its development pipeline. The company is not currently profitable, with a return on equity of -1.39. The next earnings report is expected on May 7, 2026.

Insider Buying and Selling at Scholar Rock Holding Corporation

Several insiders, including Gilman Michael, Flier Jeffrey, Burow Kristina, Peng Katie, and Reed Joshua, purchased shares on June 4, 2026. Each insider bought between 4,310 and 6,839 shares, though the transaction price was not disclosed. These purchases were not made under any pre-arranged trading plan.

Analysts Set New Price Targets

On May 8, 2026, Barclays maintained its 'buy' rating on Scholar Rock with a price target of $55. Similarly, HC Wainwright & Co. kept a 'buy' rating with a $65 target. Canaccord Genuity initiated coverage on April 21, 2026, with a 'buy' rating and a $62 target. The consensus among 16 analysts is a 'strong buy' with an average target price of $59.31.

About Scholar Rock Holding Corporation

Scholar Rock Holding Corporation is a biopharmaceutical company based in Cambridge, Massachusetts, focusing on developing treatments for rare neuromuscular diseases like spinal muscular atrophy (SMA). Under the leadership of CEO David L. Hallal, the company employs 289 people. Scholar Rock's proprietary platform targets the activation of growth factors, with key products in clinical trials aimed at conditions such as SMA and muscular dystrophies.

Bottom Line

Driehaus Capital Management's slight reduction in its Scholar Rock stake highlights ongoing interest in the biopharmaceutical company. Investors keep a close watch on these filings for insights into institutional strategies, although they reflect past decisions and not necessarily current positions. Scholar Rock's stock remains attractive to analysts, who see potential in its innovative approach to treating severe neuromuscular diseases.